Document Detail

Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy.
MedLine Citation:
PMID:  17848842     Owner:  NLM     Status:  MEDLINE    
Insufficiency fractures occur most commonly in the pelvic girdle and in the sacrum, followed by the tibia and the femoral neck. Insufficiency fractures of the femoral diaphyses are rare, with only few reported cases in the literature. The strongest associations exist with untreated osteoporosis. We describe an unusual case of multiple insufficiency fractures in a 73-yr-old Chinese woman who presented with a 10-month history of bilateral groin pain and difficulty with walking in the absence of trauma, diagnosed 18 months following the commencement of anti-resorptive therapy with alendronate. The pathogenesis of such insufficiency fractures is poorly understood, but next to low bone mineral density and micro-architectural damage likely involves other components such as changes in bone turnover and patient-related factors (e.g. non-compliance). This case report and review of the literature draws attention to some of the challenges in the diagnosis and management of such rare insufficiency fractures.
P Lee; H van der Wall; M J Seibel
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Journal of endocrinological investigation     Volume:  30     ISSN:  1720-8386     ISO Abbreviation:  J. Endocrinol. Invest.     Publication Date:    2007 Jul-Aug
Date Detail:
Created Date:  2007-09-12     Completed Date:  2007-10-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806594     Medline TA:  J Endocrinol Invest     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  590-7     Citation Subset:  IM    
Department of Endocrinology and Metabolism, Concord Repatriation General Hospital, The University of Sydney, Sydney Concord, NSW 2139, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alendronate / therapeutic use*
Bone Density / physiology*
Bone Density Conservation Agents / therapeutic use
Fractures, Spontaneous / diagnosis*,  etiology*
Osteoporosis, Postmenopausal / complications*,  drug therapy*
Pelvic Bones / injuries
Reg. No./Substance:
0/Bone Density Conservation Agents; 66376-36-1/Alendronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
Next Document:  Pregnancy in a woman with Turner syndrome and celiac disease.